Peptides used for treating cancers and, in particular, chronic lymphoid leukaemia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9745357
SERIAL NO

13203777

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE3 RUE MICHEL ANGE PARIS 75016
UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)75005 PARIS
UNIVERSITE DE BRETAGNE OCCIDENTALEBREST
CENTRE HOSPITALIER UNIVERSITAIRE DE BREST5 AVENUE FOCH 29200 BREST

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Berthou, Christian Brest, FR 4 5
Cormier, Patrick Cléder, FR 1 1
Cosson, Bertrand Taulë, FR 3 3
Czjzek, Mirjam Plougoulm, FR 3 3
Saad, Hussam Treflaouenan, FR 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00